Current Oncology,
Journal Year:
2024,
Volume and Issue:
31(12), P. 7890 - 7902
Published: Dec. 9, 2024
Advanced
breast
cancer
is
an
incurable
disease,
with
a
median
overall
survival
of
3
years,
including
in
countries
without
access
problems.
Although
chemotherapy
reserved
some
cases,
it
still
used
many
as
first-line
therapy.
The
aim
our
study
to
evaluate
the
treatment
choices
and
factors
that
influence
therapeutic
decisions.
A
retrospective
analysis
was
conducted
hormone
receptor
(+)/HER2
(−)
advanced
patients
classified
into
three
groups
according
second-line
received:
endocrine
therapy–chemotherapy,
therapy–endocrine
therapy
chemotherapy–endocrine
Additionally,
we
explored
sequencing
groups.
First-line
chosen
34%
patients.
Also,
around
60%
met
“aggressive
disease”
criteria
from
RIGHT
Choice
trial,
justifying
use
population
poor
prognosis.
Furthermore,
de
novo
progressive
disease
were
prognostic
influenced
treatment.
Regarding
survival,
this
trial
saw
increase
compared
MONALEESA
trials
(endocrine
alone
arms).
No
significant
differences
progression-free
or
found
There
higher
therapy,
being
main
decision.
Journal of Personalized Medicine,
Journal Year:
2024,
Volume and Issue:
14(7), P. 723 - 723
Published: July 4, 2024
Breast
cancer
remains
the
most
prevalent
among
women
worldwide,
driving
urgent
need
for
innovative
approaches
to
diagnosis
and
treatment.
This
review
highlights
pivotal
role
of
nanoparticles
in
revolutionizing
breast
management
through
advancements
interconnected
including
targeted
therapy,
imaging,
personalized
medicine.
Nanoparticles,
with
their
unique
physicochemical
properties,
have
shown
significant
promise
addressing
current
treatment
limitations
such
as
drug
resistance
nonspecific
systemic
distribution.
Applications
range
from
enhancing
delivery
systems
sustained
release
developing
diagnostic
tools
early
precise
detection
metastases.
Moreover,
integration
into
photothermal
therapy
synergistic
use
existing
treatments,
immunotherapy,
illustrate
transformative
potential
care.
However,
journey
towards
clinical
adoption
is
fraught
challenges,
chemical
feasibility,
biodistribution,
efficacy,
safety
concerns,
scalability,
regulatory
hurdles.
delves
state
nanoparticle
research,
applications
diagnosis,
obstacles
that
must
be
overcome
integration.
Molecular Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 4, 2025
Plasma
cell‐free
DNA
(cfDNA)
analysis
to
track
estrogen
receptor
1
(
ESR1
)
mutations
is
highly
beneficial
for
the
identification
of
tumor
molecular
dynamics
and
improvement
personalized
treatments
patients
with
metastatic
breast
cancer
(MBC).
Plasma‐cfDNA
is,
up
now,
most
frequent
liquid
biopsy
analyte
used
evaluate
mutational
status.
Circulating
cell
(CTC)
enumeration
characterization
provides
important
clinical
information
in
MBC.
In
this
study,
we
investigated
whether
CTCs
circulating
(ctDNA)
provide
similar
or
complementary
mutations.
We
analyzed
both
plasma‐cfDNA
n
=
90)
paired
CTC‐derived
genomic
(gDNA;
42)
from
90
MBC
seven
Eight
out
(8.9%)
samples
tested
using
ddPLEX
Mutation
Detection
Assay
(Bio‐Rad,
Hercules,
CA,
USA),
were
found
positive
one
mutation,
whereas
11/42
(26.2%)
gDNA
at
least
mutation.
Direct
comparison
revealed
that
mutation
rate
was
higher
(11/42,
26.2%)
than
(6/42,
14.3%)
samples.
Our
results,
sensitive
assay,
reveal
a
percentage
gDNAs
ctDNA
should
be
further
evaluated
as
an
tool
identifying
guiding
individualized
therapy.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(4), P. 494 - 494
Published: April 12, 2024
Proteolysis-targeting
chimeras
(PROTACs)
are
an
emerging
therapeutic
modality
that
show
promise
to
open
a
target
space
not
accessible
conventional
small
molecules
via
degradation-based
mechanism.
PROTAC
degraders,
due
their
bifunctional
nature,
which
is
categorized
as
‘beyond
the
Rule
of
Five’,
have
gained
attention
distinctive
approach
for
oral
administration
in
clinical
settings.
However,
development
PROTACs
with
adequate
bioavailability
remains
significant
hurdle,
largely
large
size
and
less
than
ideal
physical
chemical
properties.
This
review
encapsulates
latest
advancements
orally
delivered
entered
evaluation
well
developments
highlighted
recent
scholarly
articles.
The
insights
methodologies
elaborated
upon
this
could
be
instrumental
supporting
discovery
refinement
novel
degraders
aimed
at
treatment
various
human
cancers.
International Journal of Nanomedicine,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 6057 - 6084
Published: June 1, 2024
Introduction:
The
design
of
delivery
tools
that
efficiently
transport
drugs
into
cells
remains
a
major
challenge
in
drug
development
for
most
pathological
conditions.
Triple-negative
breast
cancer
(TNBC)
is
very
aggressive
subtype
with
poor
prognosis
and
limited
effective
therapeutic
options.
Purpose:
In
TNBC
treatment,
chemotherapy
the
milestone,
doxorubicin
(Dox)
represents
first-line
systemic
treatment;
however,
its
non-selective
distribution
causes
cascade
side
effects.
To
address
these
problems,
we
developed
platform
based
on
self-assembly
amphiphilic
peptides
carrying
several
moieties
their
surfaces,
aimed
at
targeting,
enhancing
penetration,
therapy.
Methods:
Through
single-step
process,
used
to
obtain
nanofibers
decorated
surfaces
selected
moieties.
surface
nanofiber
was
cell-penetrating
peptide
(gH625),
an
EGFR-targeting
(P22),
Dox
bound
cleavage
sequence
selectively
recognized
cleaved
by
MMP-9
on-demand
release.
Detailed
physicochemical
cellular
analyses
were
performed.
Results:
obtained
(NF-Dox)
had
length
250
nm
diameter
10
nm,
it
stable
under
dilution,
ionic
strength,
different
pH
environments.
biological
results
showed
presence
gH625
favored
complete
internalization
NF-Dox
after
1h
MDA-MB
231
cells,
mainly
through
translocation
mechanism.
Interestingly,
observed
absence
toxicity
carrier
(NF)
both
healthy
such
as
HaCaT
lines,
while
similar
antiproliferative
effect
treatment
free-Dox
50
μM
7.5
Dox.
Discussion:
We
envision
this
extremely
versatile
can
be
carry
deliver
diverse
knowledge
acquired
from
study
will
provide
important
guidelines
applications
basic
research
biomedicine.
Keywords:
self-assembling
peptides,
triple
negative
cancer,
nanofiber,
strategy,
Journal of Medicinal Chemistry,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 25, 2024
Inhibition
of
estrogen
receptor
alpha
(ERα)
signaling
is
an
established
therapeutic
approach
for
the
treatment
ER-positive
(ER+)
breast
cancers,
but
new
strategies
are
urgently
needed
to
overcome
clinical
resistance.
In
present
study,
we
describe
discovery
and
extensive
evaluation
ERD-12310A
as
exceptionally
potent
orally
efficacious
PROTAC
degrader
ERα.
achieved
a
DC
